Monopar Therapeutics Appoints Quan Vu as New CFO

Tip Ranks
2025.03.03 22:53

Monopar Therapeutics Inc. has appointed Quan Vu as the new Chief Financial Officer, effective March 3, 2025, following the termination of Karthik Radhakrishnan's employment. Vu brings significant experience in corporate and financial strategy from his previous roles in the biopharmaceutical and investment banking sectors. This leadership change is anticipated to positively influence Monopar's financial strategy and operations.

Monopar Therapeutics Inc ( (MNPR) ) has shared an announcement.

Monopar Therapeutics Inc. announced the termination of Karthik Radhakrishnan’s employment as Chief Financial Officer, principal financial officer, and principal accounting officer on February 28, 2025. The company’s Board of Directors appointed Quan Vu as the new CFO, effective March 3, 2025. Vu brings extensive experience in corporate and financial strategy, having previously served in various leadership roles in the biopharmaceutical and investment banking sectors. This leadership change is expected to impact Monopar’s financial strategy and operations positively.

More about Monopar Therapeutics Inc

YTD Price Performance: 58.01%

Average Trading Volume: 71,024

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $214.3M

Learn more about MNPR stock on TipRanks’ Stock Analysis page.

Trending Articles:

  • M&A News: Paramount (NASDAQ:PARA) Faces New Legal Headaches
  • Ford (NYSE:F) February Sales Hit a Rough Patch
  • Intel (NASDAQ:INTC) CEO Drama Fires Up in Earnest
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.